Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

NCT07059910 — Not yet recruiting, 100 participants, Assiut University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07059910
Status	Not yet recruiting
Study type	Observational
Enrollment	100 (Estimated)
Sponsor	Assiut University (Other)
Conditions	Immune Thrombocytopenic Purpura, Thyroid Disorders
Interventions	Search for thyroid disorders, Laboratory test, Steroid and eltrombopage (Diagnostic test, drug)
Dates	start 2025-07-01 (estimated), primary completion 2026-05-31 (estimated), completion 2026-08-15 (estimated), first posted 2025-07-11, last updated 2025-07-17

-Summary

Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment

Expand all sections · Collapse all

+Detailed description

We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt

+Arms and interventions

Arm	Type	Interventions	Description
Patients known ITP		Diagnostic Test: Search for thyroid disorders; Diagnostic Test: Laboratory test; Drug: Steroid and eltrombopage	Patients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study

Search for thyroid disorders (Diagnostic test), also known as Laboratory test: TSH , FT3 , FT4
Laboratory test (Diagnostic test): Search for anti thyroid antibodies
Steroid and eltrombopage (Drug), also known as Drugs used in ITP: See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?

+Outcome measures

Primary outcomes

Assess the frequency of thyroid disorders in patients with IT [Assess the frequency of thyroid disorders in patients with IT]: Screening of thyroid disorders in patients with ITP
Evaluate the treatment of thyroid disorders in improvement in platelets count. [Evaluate the treatment of thyroid disorders in improvement in platelets count.]: Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.

  * refractory ITP patients.

Exclusion Criteria:

* patients with history of thyroidectomy

  * patients with history of drug induced ITP
  * patients with history of HCV, HBV and HIV infection.
  * Patients who refuse to contribute in this study.